ocal Drug Delivery for the treatment of Periodontal Diseases
- Conditions
- Health Condition 1: 3- Administration
- Registration Number
- CTRI/2019/04/018697
- Lead Sponsor
- not applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 26
1. Patients motivated to have the therapy and willing to complete the follow-up.
2. Patients with a minimum of 20 teeth.
3. Subjects who readily give informed consent for the study.
4. Systemically healthy subjects, with deep pockets.
5. Patients with no history of periodontal therapy ij the preceding 6 months or under any antibiotic therapy.
1. Patients on systemic boron therapy, those with a known or suspected allergy to boron supplementation or curcumin.
2. Patients who have undergone periodontal therapy in the last 6 months.
3. Patients who were taking and had consumed vitamin supplements, anti-inflammatory agents, or statins in the previous 3 months.
4. Patients with any systemic disorder affecting periodontal health.
5. Patients with infectious conditions other than periodontitis.
6. Regular users of mouthwashes.
7. Chronic alcoholics
8. Those with aggressive periodontitis.
9. Patients consuming tobacco in any form, smokers, alcoholics
10. Immunocompromised and systemically unhealthy patients.
11. Pregnant or lactating females.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Probing pocket depth reductionTimepoint: baseline, post-operatively 3 months and 6 months
- Secondary Outcome Measures
Name Time Method Clinical attachment level gainTimepoint: baseline, post-operatively 3 months and 6 months